GET DAILY SIGNALSHeartSciences Inc. (HSCS): Analyst Targets Point to +129% Upside Toward $10
Key Takeaways
- The central target of $10 is the arithmetic mean of two verified analyst price targets ($8 and $12).
- At roughly $4.36, reaching $10 would require an upside of about 129%, a very large move.
- The analyst target range is wide — $8 to $12 — reflecting meaningful disagreement about the company's near-term prospects.
- Bullish support rests on FDA clearance of a first diagnostic algorithm and early commercialization of MyoVista.
- The biggest risks are pre-revenue status, a shrinking cash position, and a Nasdaq listing-compliance notice.
What the Analysts Are Saying
Coverage of HSCS remains limited. Two current, attributable targets stand out. Ascendiant Capital analyst Lucas Ward lowered his target from $9 to $8 on March 24, 2026, while keeping a Buy rating. Maxim Group has maintained a $12 target and reiterated its Buy recommendation. The arithmetic mean of these two figures is $10, and the range spans $8 to $12 — a 50% spread that highlights the uncertainty surrounding an early-stage company.
Both analysts center their case on the MyoVista device working alongside the MyoVista Insights software rollout and the expected FDA approval of the first diagnostic algorithm. Ascendiant has pointed to the scale of the U.S. ECG market — more than 100 million tests annually — as a core part of its thesis. The gap between an $8 and a $12 target reflects differing views on regulatory timing, commercial ramp, and how quickly revenue can move from pilot stage to something more substantial. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how recent price action lines up with these views.
Current Market Position and Path to the Target
HSCS last traded near $4.36, with a market capitalization of roughly $21 million. The stock has been highly volatile, with a 52-week range from about $1.63 to above $5. Moving from $4.36 to $10 implies a gain of approximately 129% — a substantial move that would require not only favorable news but also a meaningful re-rating of the company.
The path would likely hinge on regulatory milestones. HeartSciences generates only minimal revenue — roughly $4,500 in trailing twelve-month revenue — and posted a net loss near $10.3 million over the same period. Analysts’ targets therefore look past current losses and anticipate a shift toward recurring software revenue and device sales once regulatory clearance is secured and distribution expands.
Factors That Could Support a Move Higher
- Regulatory catalysts: FDA clearance of the first AI diagnostic algorithm, expected in the first half of 2026, remains central to the investment case.
- Product breadth: Pairing the MyoVista wavECG device with the device-agnostic MyoVista Insights platform could support a software-led, higher-margin model.
- Large addressable market: With over 100 million ECG tests performed annually in the U.S., early detection of cardiac dysfunction represents a sizable opportunity.
- Analyst revisions: Any upgrade to revenue estimates as commercialization begins could reinforce the existing Buy ratings.
Risks That Could Keep the Target Out of Reach
- Pre-revenue risk: With essentially no meaningful revenue, valuation rests almost entirely on future execution rather than current fundamentals.
- Cash runway: Reported cash of roughly $30,000 in the most recent quarter points to continued reliance on dilutive financing, which could pressure the share price.
- Listing compliance: The company has been flagged for failing to meet Nasdaq continued-listing requirements, adding a structural overhang.
- Regulatory and reimbursement uncertainty: Delays in FDA clearance or slow payer adoption would undermine the timeline embedded in higher targets.
Technical Levels and Market Structure
HSCS trades well off its 52-week low near $1.63 and has recently tested levels above $5. The stock’s thin float and heavy daily swings — with intraday ranges spanning from roughly $3.43 to $6.47 — make conventional support and resistance zones less reliable. The $5 area represents a notable prior ceiling, while a sustained move toward $10 would require breaking well beyond the stock’s established multi-year trading band. Psychologically, the $5 and then $10 levels are the most obvious markers on any upward trajectory.
Time Horizon and What to Watch
Analyst price targets generally reflect a research horizon of about 12 months, though the specific horizon for these two firms is not disclosed. Investors focused on the $10 target should watch the FDA decision on the first diagnostic algorithm, the company’s quarterly cash position and any new financing, Nasdaq listing-compliance updates, and early signs of commercial traction in the MyoVista Insights rollout. Any upward or downward analyst revisions, particularly from Ascendiant or Maxim Group, would also signal how the thesis is evolving.
Final Assessment
The $10 target for HeartSciences is a calculated average of two analyst targets — Ascendiant’s $8 and Maxim Group’s $12 — rather than an independently published consensus. It implies roughly 129% upside from the current price, a very large move achievable only through a sequence of successful regulatory, financial, and commercial milestones. Support rests on FDA clearance and the MyoVista product suite, while pre-revenue status, a thin cash position, and listing-compliance concerns are substantial obstacles. The wide $8-to-$12 range reflects genuine disagreement, and reaching the higher end would demand execution that has not yet been demonstrated. Investors should treat the target as an analyst-derived reference point, not a forecast, and watch the regulatory timeline and balance sheet closely.
AI Daily Buy/Sell Signals
In my own research process, I’ve found Tickeron’s AI Daily Buy/Sell Signals helpful for tracking volatile names like HSCS. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For micro-caps where price action can change quickly, it offers an efficient way to stay on top of developments without relying solely on manual screening.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for HSCS turns negative, indicating new downward trend
HSCS saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned negative. In 68 of the 75 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for HSCS turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 37 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
HSCS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HSCS crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HSCS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for HSCS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where HSCS advanced for three days, in 144 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
HSCS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. HSCS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-6.740) is normal, around the industry mean (4.142). P/E Ratio (-1.025) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. HSCS's P/S Ratio (2500.000) is very high in comparison to the industry average of (40.124).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HSCS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement